Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients

This is a Phase 3 Randomized, double-blind, Multiregional Study of Ivonescimab Combined with Chemotherapy Versus Pembrolizumab Combined with Chemotherapy for the First-line Treatment of Metastatic Non-small Cell Lung Cancer. The primary endpoint is overall survival and progression free survival assessed by investigator. The key secondary endpoints include response and safety.

Locations: Hartford Hospital, Hartford HealthCare Cancer Institute at The Hospital of Central Connecticut, Hartford HealthCare Medical Group - Manchester, Hartford HealthCare Cancer Institute - Avon, MidState Medical Center
ClinicalTrials.gov Link: https://clinicaltrials.gov/study/NCT05899608
Contacts: Christopher Sampson: Christopher.Sampson@hhchealth.org; Siobhan Reilly: Siobhan.Reilly@hhchealth.org